Biolog, Texas A&M Partner on $1M Phase II STTR to Phenotype Pathogenic Bacteria

The collaboration allows Biolog to leverage facilities and expertise surrounding pathogenic bacteria at Texas A&M that it lacks in house. Texas A&M benefits primarily from the research funding, and may stand to generate licensable intellectual property, though Biolog would likely not be the licensor of such inventions, a company official said.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.